<http://www.wikidata.org/entity/statement/Q61921280-BB727DC1-739F-441F-9431-87E9E3D0D09F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://wikiba.se/ontology#BestRank> .
<http://www.wikidata.org/entity/statement/Q61921280-BB727DC1-739F-441F-9431-87E9E3D0D09F>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://wikiba.se/ontology#Statement> .
<http://www.wikidata.org/entity/statement/Q61921280-BB727DC1-739F-441F-9431-87E9E3D0D09F>	<http://www.wikidata.org/prop/statement/P1476>	"A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study With a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching From Donepezil to an Initial Dose of 5 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease"@en .
<http://www.wikidata.org/entity/statement/Q61921280-BB727DC1-739F-441F-9431-87E9E3D0D09F>	<http://wikiba.se/ontology#rank>	<http://wikiba.se/ontology#NormalRank> .